Insulet (NASDAQ:PODD) Price Target Cut to $210.00 by Analysts at Oppenheimer

Insulet (NASDAQ:PODD) had its price objective trimmed by Oppenheimer from $300.00 to $210.00 in a research report report published on Thursday morning, Marketbeat.com reports. The brokerage currently has an outperform rating on the medical instruments supplier’s stock.

A number of other equities research analysts have also commented on PODD. Barclays reiterated an “underweight” rating and issued a $198.00 price target on shares of Insulet in a research report on Thursday. The Goldman Sachs Group reduced their price target on Insulet from $326.00 to $277.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. TD Cowen lowered Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target on the stock. in a research report on Monday, January 26th. Raymond James Financial reduced their price target on Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. Finally, Sanford C. Bernstein reduced their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research report on Thursday. Eighteen research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $257.09.

Insulet Price Performance

Shares of PODD opened at $160.40 on Thursday. Insulet has a 12-month low of $148.30 and a 12-month high of $354.88. The business has a 50-day simple moving average of $211.22 and a two-hundred day simple moving average of $263.85. The company has a quick ratio of 2.15, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The stock has a market cap of $11.11 billion, a PE ratio of 37.30, a PEG ratio of 0.89 and a beta of 1.20.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter in the previous year, the company posted $1.02 EPS. The business’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts anticipate that Insulet will post 6.27 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michael R. Minogue purchased 2,030 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were acquired at an average cost of $246.23 per share, with a total value of $499,846.90. Following the purchase, the director owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.36% of the company’s stock.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently modified their holdings of the stock. Sage Mountain Advisors LLC raised its stake in shares of Insulet by 4.6% in the third quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 33 shares during the last quarter. Glenmede Investment Management LP raised its stake in shares of Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after purchasing an additional 35 shares during the last quarter. Curi Capital LLC raised its stake in shares of Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after purchasing an additional 36 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock worth $1,261,000 after purchasing an additional 37 shares during the last quarter. Finally, Great Lakes Advisors LLC raised its stake in shares of Insulet by 1.5% in the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after purchasing an additional 40 shares during the last quarter.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 beat and guidance raise — Insulet reported Q1 revenue of $761.7M (+33.9% YoY) and adjusted EPS $1.42, topping estimates; management raised FY2026 constant?currency revenue growth to 21%–23% and reiterated margin expansion, which helped lift sentiment. Business Wire: Q1 Results
• Positive Sentiment: Omnipod international momentum — Management highlighted sharp international Omnipod revenue growth and continued geographic expansion (including new Middle East Omnipod 5 launches), supporting growth durability beyond the U.S. market. Reuters: Growth/Forecast
• Positive Sentiment: Profitability and insider buying — Adjusted operating margin expanded and EPS beat consensus; several insiders (including the CEO) bought shares recently, which can signal management confidence. QuiverQuant: Earnings analysis & insider activity
• Neutral Sentiment: Analyst ratings still mixed — Several firms reiterated buy/overweight stances even as they trimmed targets; median analyst targets remain well above current levels, leaving upside claims but greater dispersion in near?term expectations. QuiverQuant: Analyst moves & targets
• Negative Sentiment: Widespread price?target cuts — Multiple brokers lowered targets (Piper Sandler, BofA/JPMorgan/others), reflecting model resets after the print; that put near?term pressure on sentiment despite the beat. MarketScreener: Piper Sandler target cut

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.